Proove Biosciences, which sold dubious DNA tests to predict addiction risk, sells off assets as CEO departs amid criminal probe
By Charles Piller,
STAT
| 08. 31. 2017
Proove Biosciences, a formerly high-flying genetic testing firm whose science and business practices have been challenged by experts and former employees, has been placed into court-ordered receivership for “restructuring and asset sale,” according to the company’s founder and former CEO.
Proove’s founder, Brian Meshkin, said in an interview on Thursday that he no longer works at Proove, which rang up $28 million in revenue last year. Meshkin blamed the company’s fall on investigative articles published by STAT last December and February. Those articles quoted experts who expressed deep doubts about the company’s scientific claims that it could predict a patient’s likelihood of becoming addicted to opioids. “Hogwash” was the assessment of Dr. Mary Jeanne Kreek, a leading researcher on genetic links to addiction at Rockefeller University.
STAT’s investigations also described business practices — including coercing patients to take unnecessary genetic tests — that former Proove employees and outside experts described as unethical and possibly illegal.
In June, agents from the FBI and Department of Health and Human Services agents raided Proove’s offices in Irvine, Calif. to collect truckloads of documents...
Related Articles
By Antonia O'Flaherty, ABC News Australia | 03.04.2026
Fertility giant Monash IVF has agreed to pay financial settlements to families involved in two major bungles that saw two women transferred the wrong embryo.
In February 2025 the company became aware that one of its Brisbane clinic's patients had...
By Rowan Walrath and Laurel Oldach, Chemical & Engineering News | 03.04.2026
Washington, DC—At a press conference held at the US Department of Health and Human Services headquarters on Feb. 23, two doctors from the University of Pennsylvania and Children’s Hospital of Philadelphia spoke about their hope for the future of...
By Michael Levenson, The New York Times | 02.27.2026
The pharmaceutical giant Novartis has reached a settlement with the family of Henrietta Lacks, a Black woman whose cells were taken from her without her consent in 1951, when she was dying of cervical cancer in a segregated ward at...
By Jason Liebowitz, The New Yorker | 03.06.2026
When Talaya Reid was in high school, in a quiet suburb of Philadelphia, she developed fatigue so severe that she spent afternoons napping instead of going out with friends. She was lethargic at school and her grades suffered, but after...
